While these excellent studies have provided important evidence confirming the ability of PSP-derived tau to induce the three cytopathologies that characterize PSP, as well as modeling the spread of pathology throughout interconnected regions of the brain, each of these studies were primarily focussed on other tauopathies, leading to gaps in experimental design with respect to the modeling of PSP which we elaborate on below. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.